Techne
Work Here?
Overview
About Techne
Industries
Design
Real Estate
Company Size
1-10
Company Stage
N/A
Total Funding
N/A
Headquarters
London, United Kingdom
Founded
2020
Get referred to Techne
See people who can refer or advise you
Simplify's Take
What believers are saying
- June 25, 2026 Merck KGaA offered $73 per share, valuing Bio-Techne at $11.3 billion.
- May 6, 2026 spatial biology grew mid-teens, and GMP proteins grew nearly 50%.
- Management said Q4 organic growth flattens before a stronger FY2027 recovery.
What critics are saying
- June 25, 2026 Merck KGaA buyout faces shareholder investigations by Ademi and Brodsky.
- Q3 FY2026 revenue fell 2% to $311.4 million, signaling demand softness.
- Emerging biotech spending stays weak; a failed Merck deal would crush the stock.
What makes Techne unique
- Bio-Techne's 2026 portfolio spans R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics.
- Its RNAscope and COMET platforms anchor differentiated spatial biology and in situ analysis.
- Large pharma delivered six straight quarters of double-digit growth in May 2026.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Paid Vacation
Performance Bonus
Flexible Work Hours
Company News
MINNEAPOLIS, Feb. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2024. The quarterly dividend will be payable February 28, 2025, to all common shareholders of record on February 17, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide
RD Systems Hematology Controls and Calibrators has completed the Class B Certification under the new European Union In Vitro Diagnostic Regulation. This press release updates the IVDR Classification to Class B from the prior Class C. MINNEAPOLIS, Nov. 11, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its RD Systems Hematology Controls and Calibrators. This certification confirms that the products comply with the regulations and guidelines set forth by the European Union for in-vitro diagnostic devices
MINNEAPOLIS, Oct. 31, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September 30, 2023.First Quarter FY2024 Highlights. First quarter organic revenue increased by 2% (3% reported) to $276.9 million. GAAP earnings per share1) (EPS) was $0.31 versus $0.55 one year ago. Delivered adjusted EPS1) of $0.41 compared to $0.45 one year ago
MINNEAPOLIS, Aug. 8, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2023. The quarterly dividend will be payable September 1, 2023, to all common shareholders of record on August 18, 2023. Future cash dividends will be considered by the Board of Directors on a quarterly basis.Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses
MINNEAPOLIS, Nov. 1, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2022. The quarterly dividend will be payable November 28, 2022, to all common shareholders of record on November 14, 2022. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne also announced today that its board of directors has approved and declared a four-for-one split of Bio-Techne's common stock in the form of a stock dividend to make stock ownership more accessible to employees and investors. Each stockholder of record on November 14, 2022 will receive a dividend of three additional shares of common stock for each then-held share, to be distributed after close of trading on November 29, 2022. Trading will begin on a stock split-adjusted basis on November 30, 2022
There are no jobs for Techne right now.
Find jobs on Simplify and start your career today
About Techne
Industries
Design
Real Estate
Company Size
1-10
Company Stage
N/A
Total Funding
N/A
Headquarters
London, United Kingdom
Founded
2020
There are no jobs for Techne right now.
Find jobs on Simplify and start your career today